Pfizer inks marketing deal for colorectal cancer test; Zai Lab douses a hot rumor about a Hong Kong IPO
→ Pfizer has inked a deal with Madison, WI-based Exact Sciences to help promote a DNA screening test for colorectal cancer. The agreement, which extends to 2021, has the two companies sharing marketing and promotion expenses for the test. Pfizer will join Exact’s sales efforts, reaching out to physicians and health systems to promote the test called Cologuard. Pfizer, of course, will get a cut of the gross profits.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
